Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Living with cystic fibrosis - a qualitative study of a life coaching intervention

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A free and simple computerized screening test for visual field defects

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Frequency and immunophenotype of IL10-producing regulatory B cells in optic neuritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The role of gluten in multiple sclerosis: A systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: Disease modifying drugs help control the course of relapsing remitting multiple sclerosis (RRMS); however, good adherence is needed for long-term outcomes.

Objective: To evaluate patient adherence to treatment with subcutaneous interferon beta-1a using RebiSmart® and assess injection-site reactions and treatment satisfaction.

Methods: This prospective, single-arm, open-label, noninterventional multicenter Phase IV trial included disease modifying drug-experienced mobile patients with RRMS. Adherence was measured over 12 weeks. Items 13-23, 35, 37, and 38 of the Multiple Sclerosis Treatment Concerns Questionnaire (injection-site reactions and treatment satisfaction) were recorded at 12 weeks.

Results: Sixty patients were recruited (mean age 43.7 [±SD 7.9] years; 83% female; mean years since multiple sclerosis diagnosis 6.7 [SD 4.5]). Adherence data were obtained in 54 patients only due to technical problems with six devices. Over 12 weeks, 89% (n=48) of patients had ≥90% adherence to treatment. Most patients experienced mild influenza-like symptoms and injection-site reactions, and global side effects were minimal. Most patients (78%) rated the convenience as the most important aspect of the device, and most experienced no or mild pain.

Conclusion: RRMS patients treated with subcutaneous interferon beta-1a, administered with RebiSmart, demonstrated generally good adherence, and the treatment was generally well tolerated.

OriginalsprogEngelsk
TidsskriftPatient Preference and Adherence
Vol/bind12
Sider (fra-til)569-575
ISSN1177-889X
DOI
StatusUdgivet - 2018

ID: 54719627